A glimpse in critical attributes to design cutaneous film forming systems based on ammonium methacrylate by C.G.M. Gennari et al.
Accepted Manuscript
A glimpse in critical attributes to design cutaneous film forming systems based on
ammonium methacrylate
Chiara G.M. Gennari, Francesca Selmin, Silvia Franzè, Umberto M. Musazzi, Gaia




To appear in: Journal of Drug Delivery Science and Technology
Received Date: 3 April 2017
Revised Date: 30 June 2017
Accepted Date: 10 July 2017
Please cite this article as: C.G.M. Gennari, F. Selmin, S. Franzè, U.M. Musazzi, G.M.G. Quaroni, A.
Casiraghi, F. Cilurzo, A glimpse in critical attributes to design cutaneous film forming systems based
on ammonium methacrylate, Journal of Drug Delivery Science and Technology (2017), doi: 10.1016/
j.jddst.2017.07.009.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all




































A glimpse in critical attributes to design cutaneous 





Chiara G.M. Gennari*, Francesca Selmin, Silvia Franzè, Umberto M. Musazzi, Gaia M.G. Quaroni, 
Antonella Casiraghi, Francesco Cilurzo 
 5 
Department of Pharmaceutical Sciences –Università degli Studi di Milano – via G. Colombo, 71 -






*To whom the correspondence should be sent: 
Dr Chiara Grazia Milena Gennari, PhD 
Department of Pharmaceutical Sciences  
Università degli Studi di Milano  
Via G. Colombo, 71 
20133 Milano (Italy) 
Phone: +39 02 503 24640 



















A film forming system based on Eudragit® RL (EuRL) was designed aiming to evidence the 
relevance of formulative variables on the following critical attributes: film forming rate, outward 
stickiness, Young modulus (Y) and in vitro drug skin permeation. Different solvent mixtures 
(acetone and isopropanol in the range from 10:90 to 40:60 v/v), polymer concentrations (10-30 % 
w/w), and plasticizer types and concentrations (triacetin or tributyl citrate, up to 50% of EuRL) 15 
were evaluated. EuRL dissolved in 80/20 or 70/30 v/v isopropanol/acetone mixtures at the 
concentration of 20% and plasticized with tributyl citrate (20 or 30% with respect to polymer) gave 
films with negligible stickiness and Y lower than 3 MPa. This value should assure an intimate and 
prolonged contact with the skin since it was significantly lower than Y of human stratum corneum 
(55 MPa). The optimized formulations were able to sustain the skin permeation of ibubrofen, 20 
ketoprofen and flurbiprofen and evidenced the importance of each formulative variable. In 
particular, relatively slow solvent evaporation rate can determine an initial “burst” effect and can 
influence the drug permeation in the initial hours. Conversely, when the solvent evaporation rate is 





























The passive transport rate of a molecule through the skin is proportionally related to its degree of 
saturation in the applied vehicle (Cilurzo et al., 2015). Therefore, drug supersaturation in topical 
formulations can be induced to improve the penetration into stratum corneum. Systems that are 
transiently drug supersaturated, namely those systems which become supersaturated only after dose 5 
actuation, seem to be more promising as dosage forms compared to preformed drug supersaturated 
patches, since the latter need to maintain the supersaturated state during their entire shelf-life. 
Transient supersaturation entails the reduction of drug solubility in the vehicle that is applied on the 
skin surface and this is most commonly achieved through solvent evaporation (Cilurzo et al., 2015). 
The simplest approach to achieve this goal consists in the design of polymeric film forming systems 10 
(FFS) which comprises a film-forming polymer dissolved in a volatile and skin tolerated solvent. 
When they are applied and/or sprayed on the surface of the skin, the rapid solvent evaporation leads 
to the formation of a polymeric film in situ (Misra et al., 1996). The potential advantages of these 
dosage forms reside not only in the possibility to overcome the issue related to the physical 
instability of a supersaturated system, but also in a possible enhancement effect related to the 15 
solvent skin penetration during the metamorphosis of the formulation (Gennari et al., 2016; 
Frederiksen et al., 2016). The last claimed advantage of FFS is related to the cosmetic attributes of 
the film. Indeed, many patients complain about the high visibility of transdermal patches, which are 
considered cosmetically unattractive, while the formed film is supposed to be almost invisible. 
Moving to the formulative requirements, a film-forming solution should exhibit some peculiar 20 
features related to both the applied dosage form (i.e. the polymeric solution itself) and the final film. 
Firstly, the novel dosage form should quickly dry on the skin and the minimum film forming 
temperature should be below the skin surface temperature (about 32 °C). Secondly, the mechanical 
properties of the formed film should overcome the tangential stress due to the body movements. 
Finally, the formed film is required to be non-sticky to avoid adhesion to the patient’s clothes.  25 
To satisfy these requirements, a broad range of polymers (e.g. acrylates, polyurethane-acrylates, 
cellulose derivatives, poly(vinyl pyrrolidones) and silicones) were tested (Zurdo Schroeder et al., 
2007; Frederiksen et al., 2015) Among them, the use of methyl methacrylate copolymers appears of 
particular interest (Cilurzo et al., 2014; Ammar et al., 2013; Lunter and Daniels, 2012; Frederiksen 
et al., 2015; Garvie-Cook et al., 2015), even if the literature reports contrasting results on Eudragit® 30 
RL (EuRL) when it was compared to another widely used film forming material, namely 
hydroxyethyl cellulose. As an example, the skin permeability of estradiol from EuRL based films 
resulted significantly lower than that obtained with the cellulose ether (Zurdo Schroeder et al., 
















films made of hydroxyethyl cellulose. Indeed, it was demonstrated that both tensile strength and 35 
percent elongation at break of the films were improved by mixing in appropriate ratio cellulose and 
EuRL (Asasutjarit et al., 2014). However, a systematic study of the formulation variables, namely 
solvent composition, polymer concentration, nature and amount of plasticizers, on the FFS 
properties is still lacking.  
The current work aimed to study the effect of formulation compositions on technological and 40 
biopharmaceutical properties of FFS based on EuRL solubilized in a mixture of acetone and 
isopropyl alcohol in different ratios. This volatile vehicle was selected since both solvents have a 
regulatory approval for topical use.  
The effects of solvent systems as well as the addition of the plasticizer, namely triacetin or tributyl 
citrate, were preliminary evaluated on drying time, outward stickiness and mechanical properties. In 45 
particular, since a reference for the tensile properties of the formed film is not established, the 
elasticity of human stratum corneum was preliminary determined and used as reference. 
The performances of the optimal formulations were further investigated studying the skin 
permeation of three different drugs, namely flurbiprofen, ibuprofen and ketoprofen. 
 50 
2. MATERIALS AND METHODS 
 
2.1 Materials 
Eudragit® RL PO (poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl 
methacrylate chloride); molar proportions of the monomer units 1:2:0.2; weight average molar mass 55 
32 KDa, EuRL) was kindly supplied by Rofarma Italia (Italy). Tributyl citrate (TBC) and triacetin 
(TRI) were provided by Morflex (USA) and Sigma Aldrich (Italy), respectively. Isopropanol and 
acetone were purchased by VWR International (Italy). Flurbiprofen (FP) and ketoprofen (KP) were 
purchased from Farmalabor (Italy) and S-ibuprofen (IB) from Francis (Italy). 
All solvents were of analytical grade, unless specified. 60 
 
2.2 Preparation of polymeric FFS 
Film-forming systems (FFS) were prepared by adding 10, or 20, or 30 (%, w/w) EuRL to different 
mixtures of isopropanol and acetone (ratios: 90:10, 80:20, 70:30, 60:40 %, v/v) with or without the 
selected plasticizer. Each solution was stirred overnight to ensure the complete swelling of the 65 
polymer in the solvent blend. 

















2.3 Characterization of the polymeric FFS 
The preliminary screening of placebo compositions was carried out keeping in consideration the 70 
FFS drying time, the stickiness and cosmetic attributes of the formed film. Briefly, a small volume 
of the formulations was applied with a micropipette onto a plastic liner and the solvent was allowed 
to evaporate to form the film. The applied volume was fixed at 35 µL/2.5 cm2 as this amount is 
small enough to be applied without flowing away from the application site. No-sticking films 
formed within 10 min and showing good cosmetic attributes were considered adequate for the aim 75 
of this work. The drying time was visually checked by evaluating the formation of a fingerprint on 
the film surface. This approach has been selected since the other method reported in literature, 
namely the use of a glass slide (Zurdo Schroeder et al., 2007; Frederiksen et al., 2015), did not 
permit to discriminate the formation of a dried, but sticky film.  
The adhesive properties were preliminary evaluated by a thumb tack test (Minghetti et al., 2004), on 80 
the dry films according to the following score system: no adhesion, poor adhesion and good 
adhesion. 
Afterwards, TBC or TRI were added to the most promising FFS in order to evaluate the effect of 
the plasticizers on the flexibility of films. To select the plasticizer concentration, the glass transition 
temperature (Tg) of films made by casting a polymeric mixture in isopropyl alcohol, containing the 85 
selected plasticizer in different ratios, was evaluated by differential scanning calorimetry (DSC) 
analysis (DSC1 Instrument, Mettler-Toledo, CH). Briefly, 20 mg (± 0.01 mg) exactly weighted 
samples were sealed in aluminum pans and heated in inert atmosphere (70 ml min-1 of N2). The 
reference was a pan containing aluminum oxide (Lunter and Daniels, 2012). The equipment was 
calibrated with an indium sample. Films were scanned at 20 K/min from 20 to 80 °C in order to 90 
erase polymer thermal history, then cooled down to – 50 °C at 20 K/min and re-heated up to 80 °C 
at 20 K/min. Tg was calculated as the inflection point in the second heating ramp.  
 
2.4 Mechanical testing 
Human stratum corneum isolation - The permeation studies were performed using the abdominal 95 
skin from female donors, who underwent cosmetic surgery and signed an informed consent for the 
use of the biological sample for research purposes (Franzè et al., 2015). After removing the 
subcutaneous fatty tissue, the skin was kept frozen until further use. For the stratum corneum 
isolation, skin sections were cut into squares of about 2.5 cm2 and were immersed in water of 60 °C 
for 60 s according to an internal protocol (Gennari et al., 2016b). Afterwards, the epidermis was 100 
carefully removed from the underlying tissue with the help of forceps and visually inspected for 
















solution in pH 7.4 phosphate buffer (Gennari et al. 2016b). After digestion, the underlying tissue of 
epidermis was scraped away and the remaining stratum corneum was washed in cold MilliQ® water. 
The stratum corneum samples were cut in 8×16 mm specimen, transferred into Petri dishes and left 105 
to equilibrate in a humidifier at 25 °C and 75% relative humidity using a saturated solution of 
sodium chloride, over a 12 h period. 
Film preparation - Placebo films were prepared by a solvent casting technique by using a 
laboratory-coating unit Mathis LTE-S(M) (Mathis, CH), equipped with a blade coater. The coating 
thickness was set in order to obtain a dried film of about 50 µm. The FFS was spread on the release 110 
liner and dried at 32±1 °C for 20 min. Film samples were cut in 7×20 mm specimen and stored at 
25 °C until use. 
Probe tack test - Probe tack test measures the force required to separate the test probe tip from the 
film sample by using a tensile testing machine equipped with a 50 N cell load transducer (Instron 
5965, ITW Test and Measurement Italia S.r.l., Italy). The experiments were set according to an 115 
internal standard procedure (Cilurzo et al. 2015b). Briefly, a flat stainless steel probe (diameter: 6 
mm) was placed about 0.05 mm above the sample. Then, the probe was lowered onto the film 
surface and a constant force of 0.05 N was applied onto the sample for 5 s and, finally, the probe 
was removed at the debonding rate of 0.1 mm/s. The stress (σ) values for each experiment were 
calculated according to the following equation: 120 
σ = F/A 
where F is the force registered during the detachment and A is the probe surface area. 
The results are expressed as the mean ± SD of four samples for each formulation. 
Tensile test - Stratum corneum strips (8×16 mm) or film samples (7×20 mm) were positioned 
between two pneumatic jaws of the tensile testing machine, separated at a distance of 8 mm. The 125 
lower jaw remains fixed, whilst the upper jaw connected to the load cell mounted on top of the 
crosshead rises at a speed of 2 mm min-1. Young modulus (Υ) was calculated as the slope of the 
linear portion of the stress-strain curve. The results were expressed as force per unit area (MPa). 
Individual experiments were performed on four samples of stratum corneum or film. 
 130 
2.5 Thermogravimetric analysis 
Thermogravimetric measurements (TGA) were carried out using a TGA 2050 Thermogravimetric 
Analyser (TA Instruments, USA). Samples of 80 µL FFS were held at 32 °C under nitrogen 
atmosphere and mass losses versus time were measured over 1 h. The higher the ∆m min-1 value 

















2.6 Polarized optical microscopy 
Crystallization of drugs from the polymeric FFS was evaluated by a polarized optical microscopy 
(Axiolab E re, CarlZeiss, Germany) equipped with 10x objective. A suitable volume of each 
solution was spread on a microscope glass slide and allowed to dry in a water vapor saturated 140 
chamber at 32 °C, to mimic the conditions of the skin penetration experiments. The presence or 
absence of drug crystals was noted. 
 
2.7 In vitro drug permeation 
The human epidermis samples were prepared as described above. Prior to experimental use, the 145 
integrity was assessed measuring their electrical resistance (voltage: 100 mV, frequency: 100 Hz; 
Agilent 4263B LCR Meter, Microlease, Italy). Samples with an electrical impedance resistance 
higher than 30 KΩ·cm2 were used for the in vitro permeation experiments (Gennari et al., 2016b). 
The epidermis sample was mounted on the Franz diffusion (PermeGear, USA) cell with an effective 
penetration area of 0.636 cm2. The receptor compartment (volume: ~ 3.0 mL) was filled with 150 
degassed 0.9% w/v NaCl solution. Special care was given to avoid air bubbles between the buffer 
and the epidermis in the receptor compartment. The upper and lower parts of the vertical Franz cell 
were sealed with Parafilm® and fastened together by means of a clamp. Volumes of 10 µL FFS 
were applied uniformly on the epidermis sample as donor phase. The system was kept at 37±1 °C 
by means of a circulating water bath so that the skin surface temperature was at 32±1 °C and the 155 
receiver medium was continuously maintained under stirring with a magnetic bar.  
The experiments (three replicates per formulation) were performed over a 24 h period under non-
occlusive conditions. During this period, 200 µL samples were drawn at predetermined intervals 
and replaced by aliquots of fresh receptor fluid. Sink conditions were maintained throughout the 
experiment. Samples were analysed by HPLC according to the methods described below.  160 
The cumulative amount permeated through the skin per unit of area was calculated from the 
concentration of each substance in the receiving medium and plotted as a function of time.  
The average flux (J) was calculated over the 1-5 h period of time.  
 
2.8 Drug assay 165 
The drug concentrations in the receiving media were determined by HPLC assay (HP 1100, 
Chemstation, Hewlett Packard, USA). The following chromatographic conditions were used: 
Column: HyperCloneTM 5µm BDS C18 130, 150×4.6 mm (Phenomenex, USA); mobile phase: 
acetonitrile/ pH 2.6 water (60/40, % v/v); flow rate: 1.5 mL/min; wavelengths: 246 nm (FP), 225 
















were determined from standard curves in the 0.1-50.0 µg/mL range. The retention time was 
approximately 2.5 minutes for FP, 3.0 min for IB and 1.8 min for KP. The method provided good 
precision and linearity in the required concentration range (R2=1.00000 for FP, R2=0.99995 for IB, 
R2=0.99999 for KP). 
 175 
2.9 Statistical analyses 
Tests for significant differences between means were performed by ANOVA followed by Tukey 
post hoc analyses (OriginPro 2015, OriginLab, USA).  
 
3. RESULTS AND DISCUSSION 180 
 
3.1 Formulation study 
The preliminary screening of placebo compositions was carried out in vitro keeping in 
consideration the FFS drying time, the stickiness, measured qualitatively by thumb tack test, and the 
cosmetic attributes of the formed film. No-sticking films formed within 10 min and showing good 185 
cosmetic attributes were considered adequate for the aim of this work. 
The formulations prepared with the highest EuRL concentration or an acetone content higher than 
30% required more than 10 min to completely dry. On the other hand, the lowest polymer 
concentration did not allow the formation of a uniform film. Thus, 20% w/w EuRL solutions in 
isopropanol/acetone at the ratios in the 90:10-70:30 range were considered worthy to design a FFS 190 
formulation. 
Since EuRL presents a Tg at about 63 °C, the addition of a plasticizer is mandatory to decrease Tg 
below the skin surface temperature (~ 32 °C), in order to satisfy the requirements of flexibility and 
elongation necessary to assure a proper skin/dosage form contact. On the other hand, an excess of 
plasticizer concentration in the formed film can affect its properties since it is generally recognized 195 
that when the Tg is about 25-45°C lower than the application temperature the material can become 
sticky (Zosel, 1985). Since the skin surface temperature is about 32 °C, it is reasonable to suppose 
that materials with a Tg lower than -10°C are sticky (Cilurzo et al., 2014). On the bases of these 
considerations we established that the Tg of the formed film should be in the +30 °C to -5 °C range.  
In order to avoid the influence of the solvent and the drying process, Tg was calculated on the 200 
second heating ramp. As summarized in Table 1, the optimal concentration of both the selected 
plasticizers was about 20-30%. However, the outward stickiness can be influenced not only by the 
extent of plasticizer, but also by the solvent composition, which can lead to a different three 
















the stickiness of the preformed films was also determined by probe tack test (Table 2). 205 
Formulations at the highest isopropanol content caused the formation of films adhesive on the outer 
surface, independently of the plasticizer content. A similar behavior was evident for films 
plasticized by 30% w/w TBC or TRI obtained from a 70:30 v/v isopropanol/acetone solution and, 
therefore, the formulations nos 1-4, 7, 8, 10-12 were discarded (Table 2).  
The tensile properties of the selected formulations were determined and compared to those of the 210 
human stratum corneum. In this case the acceptance criterion was defined so that the elastic 
modulus of the formulation should not exceed that of the stratum corneum to assure an intimate and 
prolonged contact after topical application. Indeed, the film should possess tensile properties that 
allow to accommodate normal skin mechanical responses due to tangential stresses related to body 
motions (Yu et al., 2016; Garvie-Cook et al., 2015). 215 
When comparing data reported in literature about mechanical properties of skin, there is a quite 
evident variation, because of the specimen location, the variability of biological tissues and the 
experimental set ups (in vitro or in vivo). Overall, the results enlisted in Table 2 are included within 
the ranges found in literature for the in vitro tensile tests. Indeed, depending on the anatomic origin 
of samples and operative conditions, the in vitro values of elastic modulus ranged from 3-150 MPa 220 
(Annaidh et al., 2012). 
Therefore, a maximum value of 3 MPa was established for the selection of the suitable formed film 
in agreement with the threshold selected for other applications of films on the skin and, therefore, 
assumed as ideal to cover the range of elastic skin response (Yu et al., 2016). 
The addition of 20% w/w of TBC or TRI allowed obtaining films with the Young’s moduli lower 225 
than that of the skin (Table 2) and, therefore, an appropriate flexibility. As expected, the higher the 
plasticizer concentration, the lower the Young’s modulus value of the formed film (Table 2). The 
data also underlined that the Young’s modulus was not influenced by the organic solvent 
composition, but only by the type and content of plasticizer; in particular, TBC resulted more 
effective in reducing the Young’s modulus values. In general, the current data were in agreement 230 
also with the results obtained by using nanoindentation to determine the elastic moduli of various 
films prepared with Eudragit® RS dissolved in ethanol, with or without a plasticizer and/or 
betamethasone 17-valerate (Garvie-Cook et al., 2015). Moreover, the authors provided that the 
presence of the drug in these formulations had no significant effect on the mechanical properties of 
the films (Garvie-Cook et al., 2015). Despite the elastic moduli determined by AFM (Y = 0.3 GPa) 235 
were different an order of magnitude to that determined by texture analysis in the current set of 
experiments (Y = 55 MPa), the minimum plasticizer concentration needed to obtain a flexible 
















adhesive properties were not taken in consideration. Our results suggest that in the formulation of a 
FFS three different techniques, namely DSC, probe tack test and tensile test, should be combined to 240 
identify the optimal range of each main formulative variables (i.e. the polymer concentration, the 
type and extent of plasticizer and volatile solvent composition).  
The optimal FFSs resulted the formulations nos 5, 6 and 9. They were loaded with 4 % w/w FP, IB 
or KP (Table 3) to investigate the skin permeation process of such model drugs. 
 245 
3.2 In vitro human skin permeation 
Drug permeation profiles from FFS are illustrated in Figure 1a-c. In case of FFS loaded with FP 
and IB, both the solvent mixture and the plasticizer influenced the drug permeation profiles, but in 
different ways. The highest amount of FP permeated was obtained using the isopropanol/acetone 
mixture at the volume ratio of 80:20 (Formulation FP1, Table 3), which showed also an initial 250 
“burst” effect. This result could be explained on the basis of the mechanism of drug deposition from 
a volatile solvent system which carries the drug into the upper layer of the stratum corneum prior to 
evaporation. The longer the contact time, the deeper the penetration of the solvent and drug into the 
epidermis. A too fast evaporation rate leads consequently to a short residence time that can limit the 
drug penetration (Santhanam et al., 2005; McAuley et al., 2010). In other words, the drug 255 
absorption rate can be expected to be inversely proportional to the evaporation rate of the volatile 
solvent. Comparing the permeability results of FP loaded formulations to the volatile solvent 
evaporation data obtained by TGA analysis (Table 3), FP1 showed a lower evaporation rate than 
FP2 and FP3, representing the main driving force influencing drug permeability. The above-
suggested mechanism of drug delivery from a FFS vehicle can also help to explain the permeation 260 
profile from FP1: the initial burst effect can be ascribed to the slow evaporation rate of the solvent 
system that subsequently enhances the drug flux and the total drug permeated amount. Moreover, 
the FP permeation appears negatively influenced by the plasticizer content: the higher the 
plasticizer content (FP3), the lower the permeated amount (Table 3). This result cannot be related 
to the TGA data, since there were no significant differences between the solvent evaporation rate of 265 
FP3, namely the formulation with the highest plasticizer content, and FP2, namely the formulation 
prepared with the highest acetone content. Therefore, this feature might be explained taking into 
account the solubilizing effect of the plasticizer, which reduced the drug thermodynamic activity in 
the film and, consequently, decreased its flux through the skin (Tukey test, p=0.048).  
In the case of IB loaded FFS, the drug permeation was positively influenced by the plasticizer 270 
concentration (IB3) and the drug permeation profiles followed the rank order: IB3>IB2>IB1 (Tukey 
















governing the extent of skin permeation in the first hours appears the solvent evaporation rate. 
Indeed, the faster the evaporation rate, the lower the permeated amount (Table 3). It can be also 
supposed that the addition of TBC could affect the solubility of the drug in the matrix, causing an 275 
improvement of the partition of IB from the film toward the skin.  
Finally, the three formulations loaded with KP, which presented the same evaporation rate, showed 
no significant differences in their drug permeation profiles (One way ANOVA p=0.29. Table 3), 
suggesting that only the skin barrier properties dictated the diffusion process. 
Aiming to investigate the effect of drug concentration on the performances of drug loaded FFS, the 280 
formulation FP1, which presented a “burst effect”, was selected to carry out further in vitro 
experiments, varying or the donor phase volume or the drug concentration in the FFS. In particular, 
the following modifications of the experimental protocol were considered: (a) increasing the applied 
volume to 100 µL, while maintaining constant the drug concentration at 4% w/w; or (b) increasing 
the volume of the donor phase (20 µL instead of 10 µL) and decreasing the drug concentration (2% 285 
w/w) in the FFS; or (c) increasing the drug concentration (8% w/w) and applying 10 µL of FFS as 
donor phase. As expected, both the increase of drug concentration and the applied volume led to an 
improvement of the FP amounts permeated through the human epidermis (Tuckey test p< 0.05, 
Table 3). It is noteworthy that the flux of FP by the film containing highest drug concentration 
changed over time. Indeed, the FP flux was high over the first five hours following application, but 290 
it was reduced between 7 and 24 h (Figure 2). A similar pattern was also reported for 
methylphenidate films having similar composition (Edwards et al., 2017) and it was attributed to a 
drug crystallization, which reduced the drug availability to the partition from the donor 
compartment toward the stratum corneum. Indeed, the film, after dismounting from the Franz 
diffusion cell, showed some signs of cloudiness and small crystals were observed by light 295 
microscopy on dried film 8 h after having deposited on glass slide a FFS loaded by 8% w/w (data 
not shown). 
Conversely, the concomitant increase of the applied volume and the decrease of the drug 
concentration, to apply the same dose (see formulations FP1 (10 µL) and FP4 Tukey test p=0.025, 
Table 3), significantly affected both the FP flux and the amount permeated after 24 h. This might 300 
be attributed to a lower thermodynamic activity of the drug in the film, confirming that it is the 
more relevant feature influencing skin permeation, when the evaporation rate can be assumed 
comparable. 
 
















This work allowed to individuate the formulative space to design a film forming solution based on 
EuRL and evidenced that not only the drug thermodynamic activity, but also the solvent 
evaporation rate significantly influenced the skin permeation from FFS. The relevance of these two 
formulation parameters is strictly related to the loaded drug, even within the same class of 
compounds (e.g., in our case the aryl-propionic acids). In particular, the vehicle composition, apart 310 
from its function to solubilize the other excipients and the drug, can influence the initial delivery of 
drug into the skin, according to the solvent evaporation rate: the lower the evaporation rate, the 
higher the burst effect and the flux in the initial hours following drug application.  
The second investigated aspect deals with the influence on skin permeation of the drug 
concentration and the applied amount of dosage form. In this case the main criticism is related to 315 
the drug crystallization that can occur also in relatively short period of time affecting the whole 
permeation process through the skin, as evidenced in the case of the FSS loaded with 8% w/w FP. 
Finally the obtained data evidenced that the critical attributes that should be considered in the 
design of film forming formulations, are the outward stickiness, which was scantly investigated till 
now, and the elasticity of the formed film, other than the film forming rate and the 320 
biopharmaceutical performances. 
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Figure captions: 330 
 
Figure 1 – Drug permeation profiles from FFS obtained by applying 10 µL FFS loaded by FP (a), 
IB (b) and KP (c) on the Franz diffusion cells. Error bars represent standard deviation. 
 
Figure 2 - FP permeation profiles from FFS obtained by varying the donor phase volume (10 µL or 335 
100 µL FP1) or by varying the drug concentration in the donor phase, namely 10 µL at 2% w/w 
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100 -- -- 63±1 
90 10 -- 43±4 
80 20 -- 27±1 
70 30 -- 19±1 
60 40 -- -20±1 
50 50 -- -26±2 
90 -- 10 40±2 
80 -- 20 18±1 
70 -- 30 13±2 
60 -- 40 -7±5 















Table 2 – Tackiness (σ) and Young’s modulus (Y) of films obtained from FFS made of 20% EuRL 















1 90/10 20 -- <5 3.61±0.52 n.d. 
2 90/10 30 -- <10 4.96±1.63 n.d. 
3 90/10 -- 20 <5 5.50±0.18 n.d. 
4 90/10 -- 30 <10 10.37±2.88 n.d. 
5 80/20 20 -- <5 0.62±0.16 3.0±0.3 
6 80/20 30 -- <10 0.96±0.33 0.5±0.0 
7 80/20 -- 20 <5 0.66±0.16 31.9±10.5 
8 80/20 -- 30 <10 0.69±0.23 < 0.1 
9 70/30 20 -- <5 0.31±0.00 3.7±0.5 
10 70/30 30 -- <10 12.63±3.24 n.d. 
11 70/30 -- 20 <5 0.28±0.01 40.5±13.1 
12 70/30 -- 30 <10 6.05±2.53 n.d. 
n.d.: not determined.  














Table 3 – Permeation data obtained by applying as donor phase FFS loaded with flurbiprofen (FP), 
ketoprofen (KP) or S-ibuprofen (IB) and drying rate expressed as mass variation (∆m) determined 
















FP1 4 80/20 20 10 36.43±4.89 2.19±0.51 0.991±0.031 
100 117.83±13.34 5.78±0.14 
FP2 4 70/30 20 10 25.23±6.57 1.49±0.40 1.366±0.008 
FP3 4 80/20 30 10 11.39±5.50 0.62±0.27 1.383±0.015 
FP4 2 80/20 20 20 24.80±5.69 1.64±0.86 1.139±0.040 
FP5 8 80/20 20 10 73.50±6.14 3.90±0.60 1.167±0.079 
KP1 4 80/20 20 10 34.62±15.71 1.98±0.78 1.208±0.042 
KP2 4 70/30 20 10 40.49±4.13 3.19±0.97 1.327±0.008 
KP3 4 80/20 30 10 39.06±0.52 3.58±1.68 1.071±0.093 
IB1 4 80/20 20 10 30.21±9.63 1.33±0.46 1.242±0.016 
IB2 4 70/30 20 10 50.35±2.74 3.31±0.29 1.172±0.004 
IB3 4 80/20 30 10 71.33±13.14 4.62±0.87 1.063±0.024 
* Solution loaded in the donor compartment of Franz cell 
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